Editor in Chief Dr KK Aggarwal, Padma Shri Awardee Dated:06 February,2020
Cancer signs may appear decades before diagnosis
The Pan-Cancer Project sequenced the genomes of 38 types of cancer in 2,800 patients.
TOKYO: A massive, decadelong study sequencing the genomes of dozens of cancers has revealed the secrets of how tumours form and may pave the way for better and more targeted treatment. The Pan-Cancer Project sequenced the genomes of 38 types of cancer in 2,800 patients.
Their work produced a host of new discoveries — from the number and location of so-called driver mutations that push cells to reproduce uncontrollably, to the surprising similarities between cancers found in different types of tissue....read more
5% less cases on 5th Feb, 3723 cases as against 3927 on 4th Feb; similarly on 28th Jan, cases dropped
CMAAO Update 6th February on 2019-nCoV
The government in Delhi on Saturday set up a round-the-clock National Centre for Disease Control Call Centre (+91-11-23978046) to attend to public queries.
Kerala government declares coronavirus as a state emergency. Three primary cases in North, South and Central Kerala (Kasaragod district in north Kerala, Thrissur in central Kerala and Alappuzha in South Kerala). Four Karnataka districts bordering Kerala ....read more
Temporary hospital and beds made by China to tackle coronavirus can be the answer to tackle Kota- and Muzaffarpur-like children deaths in future
India must learn how to tackle crisis from China, the way they are managing coronavirus and bird flu.
1.Chinese authorities imposed lockdown measures on ten cities in an effort to contain the outbreak of coronavirus.
2.China built a specialized hospital [Huoshenshan Hospital] in just 10 days as part of efforts to fight coronavirus. A second facility with 1,500 beds is also being opened....read more
Health Sutras By Dr K K Aggarwal
Restricting salt intake to less than 6gm per day can reduce upper blood pressure by 2-8 mmHg
Healthcare News Monitor
Pharmabiz India - Laxmi Yadav
The unfair practice of supplying medicines meant for hospital use to hospital pharmacies in violation of Drugs and Cosmetics (D&C) Act, 1940 and Rules thereunder has become widely rampant in the country. This according to sources has badly impacted pharmaceutical trade in the country. Some major pharmaceutical companies have been identified for diverting drug supplies meant for patients at the point of care to pharmacies located at the premises of hospitals in contravention to norms. For instance, Enzoflam tablets, PAN-D tablets, PAN 40 tablets manufactured by Alkem Laboratories with stamp "for the use of hospital and nursing homes only” have been found to have billed in the name of hospital pharmacies at wholesale rate. As per norms, medical stores at hospital premises are supposed to get extra strips of the tablets free. Fake orders for medicine supplies have been reportedly made without the knowledge of hospital administration. The products or medicines in such cases of illegal practice were not labeled in accordance with the provisions of Rule 96(1) (v), 96(7) (vi) of D& C Rules 1945. Hence they are deemed to be "misbranded" drugs as per section 17(b) read with Rule 96(7)(v), 96(7)(vi) stipulating drug labeling norms and are punishable as per section 27(d) of the provisions of D&C Act. Besides this, Alkem has also allowed hospital pharmacies to engage in profiteering. The products have been supplied to hospital pharmacies at cheaper rate which are usually sold to patients at exorbitant prices. For instance, the hospital medical stores get a strip of Enzoflam for Rs.45 whereas pharmacies near hospital premises get a strip of Enzoflam for Rs.85.
Pharmabiz India - Aswani Maindola
The government needs to relax the norms for manufacturing of vaccine, which are creating hurdles in attracting more investments in this field. Experts say that the guidelines to manufacture the vaccines are complicated and overlapping in different states within India, which require multiple testing and approvals in order to get a license. This leads to delay in release of the vaccines and thereby impact the general health of the masses. Dr Davinder Gill, the outgoing CEO of Hilleman Labs, says vaccines are more complex bio-products unlike pharmaceutical products which is why not many companies are investing in vaccines. “Part of the problem is that the guidelines to manufacture and test these vaccines are quite complicated. For instance, different states have different guidelines for the manufacturing of the vaccines and the problem is such that requires the manufacturers, who are operating in one state, to conduct tests for the same vaccine again if the manufacturer wants to sell it in some other state. At the same time, there are state level guidelines that a manufacturer has to comply with, along with the central level guidelines,” said Dr. Gill. He added that there is a dire need for the union and the state governments to come together and through discussions with the manufacturers, harmonize the guidelines for pan India implementation. Hilleman Laboratories is a Delhi-based global vaccine research and development organization formed through a joint venture partnership between Merck & Co and Wellcome Trust.
Coronavirus kills 'hero' Chinese doctor who sounded alarm as toll passes 630
ET Healthworld- Reuters
A Chinese doctor who tried to warn the world about a new coronavirus died of the disease on Friday, prompting an outpouring of sorrow as the death toll passed 630 and Beijing declared a "people's war" on the rapidly spreading pathogen. Li Wenliang, 34, died in the early hours of the morning at the hospital where he worked and first raised the alarm about the new coronavirus in the central Chinese city of Wuhan, the epicentre of the outbreak, hospital officials said. An ophthalmologist, Li was one of eight people reprimanded by Wuhan police last month for spreading "illegal and false" information about the coronavirus, a flu-like pathogen that since triggered a global health emergency. His messages to a group of doctors on Chinese social media warning of a new "SARS-like" coronavirus - a reference to Severe Acute Respiratory Syndrome (SARS) which killed almost 800 people around the world in 2002-2003 - triggered the wrath of Wuhan police. China was accused of trying to cover up SARS. He was forced to sign a letter on Jan. 3 saying he had "severely disrupted social order" and was threatened with criminal charges. Chinese President Xi Jinping had earlier sought to reassure his citizens and the world that China would beat the coronavirus. "The whole country has responded with all its strength to respond with the most thorough and strict prevention and control measures, starting a people's war for epidemic prevention and control," Xinhua news agency quoted him as saying.
ET Healthworld- Chethan Kumar
In a major breakthrough for global preclinical response to the novel coronavirus (nCoV) outbreak, a team led by an overseas citizen of India has grown the first batch of the virus outside China in sufficient stocks to cater to forthcoming studies in the highsecurity lab of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia. While researchers at Australia’s Doherty Institute had last week managed to isolate the virus from a human sample, the growth of the virus at CSIRO assumes importance given that it has the mega scale needed to conduct preclinical studies. Confirming the development, Professor SS Vasan, who leads the CSIRO Dangerous Pathogens Team, told TOI: “We thank our Doherty Institute colleagues who shared their isolate with us promptly. It is quicker to work with the real virus to expedite preclinical studies on the relative efficacy of vaccine candidates under development.” Vasan, who is the principal investigator of CSIRO’s preclinical response project in partnership with the Coalition for Emergency Preparedness Innovations (CEPI) to accelerate preclinical evaluation of vaccines, said: “My colleagues at the Australian Animal Health Laboratory are also working on diagnostics, surveillance and response. Another part of the CSIRO (Manufacturing) is supporting the scaleup of vaccine antigens being developed by the University of Queensland.”